Benign Prostatic Hyperplasia (BPH) PGx Test
Test Description
The Benign Prostatic Hyperplasia (BPH) PGx Test is intended for individuals undergoing treatment for benign prostatic hyperplasia or associated lower urinary tract symptoms who may benefit from personalized pharmacogenetic-guided therapy. This panel evaluates clinically relevant genetic variants in the CYP2D6 gene that may influence the metabolism, efficacy, and tolerability of medications commonly prescribed for BPH management, including tamsulosin and mirabegron. Individuals with altered CYP2D6 metabolism may experience differences in drug response or increased risk for adverse effects, and pharmacogenetic testing may help guide medication selection and dose optimization to improve therapeutic outcomes.
Ordering Information
Turnaround Time: 3-7 business days
Preferred specimens: Saliva
Alternate specimens: Buccal Swab
Clinical Description
Medications used to manage benign prostatic hyperplasia, including alpha-blockers and 5-alpha reductase inhibitors, may demonstrate variability in efficacy and tolerability among individuals. Genetic differences affecting drug metabolism and receptor response can contribute to this variability. Pharmacogenomic testing may support more precise medication selection and dosing, helping to improve symptom control and reduce adverse effects.
Panel Information
| Medication | Gene |
| Tamsulosin, Mirabegron | CYP2D |
Frequency of Cytochrome P450 (CYP2D6) Metabolizer Types in the Population
| Cytochrome | Poor metabolizer | Intermediate metabolizer | Normal metabolizer | Rapid or ultra-rapid metabolizer |
| CYP2D6 | 4-7% | 9-35% | 50-90% | 2-3% |
Tagged Genes
- Evans WE, McLeod HL. Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538–549.
- Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease: implications for personalized medicine. Pharmacol Rev. 2013;65(3):987–1009.
- Cavallari LH, Lee CR, Beitelshees AL, et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11(2):181–191. doi:10.1016/j.jcin.2017.07.022
- Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non–ST-elevation myocardial infarction. Circulation. 2012;126(7):875–910. doi:10.1161/CIR.0b013e318256f1e0
- Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–323. doi:10.1038/clpt.2013.105
- Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017.
- Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376(9753):1658–1669. doi:10.1016/S0140-6736(10)60310-8
- The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med. 2008;359(8):789–799. doi:10.1056/NEJMoa0801936
- Clinical Pharmacogenetics Implementation Consortium (CPIC). Genes–drug pairs.
- U.S. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling.